Clinical Trials

Olzapene Study Yields Benefits for Cancer Patients

Research by Rudy Navari confirms Olanzapine curbs chemotherapy-induced nausea.

Trial	Principal Investigator	Contact Information
Olanzapine versus Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting: A Phase III Randomized Trial	Rudolph M. Navari, M.D.	574-204-6700
Treatment of Cancer-related Anorexia with Olanzapine and Megestrol Acetate	Rudolph M. Navari, M.D.	574-204-6700
A Randomized Phase II Trial of Neoadjuvant Therapy of Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC	NSABP	Cindy Nagy, R.N. 574-204-6700
A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813) (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant	SWOG	Cindy Nagy, R.N. 574-204-6700
Collection of Blood, Body Fluids, Bone Marrow, Tumor, or Tissue Samples from Patients with Pathologically Defined Neoplasms and Blood or Body Fluids from Normal Volunteers	Cancer Care Partners	Cindy Nagy, R.N. 574-204-6700